Skip to content
Screener

Net Income at other companies

Merck & Co. logo
Merck & Co.MRK
-$1.34B-130%
Amgen logo
AmgenAMGN
$2.38B+65.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.3B-6.8%
RFL
Rafael Holdings, Inc.RFL
-$4.23M+11.6%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-$127.55M-2.8%
Arvinas logo
ArvinasARVN
-$57.6M-169%

Other financials

Income statement

See full
Revenue$3.7M-80.7%
Operating income-$64.9M-82.0%
EPS (diluted)-$0.52-247%

Balance sheet

See full
Cash & equivalents$424.2M-24.8%
Total debt$82.0K-75.0%
Total equity$631.4M-18.9%
Total assets$704.5M-13.6%

Cash flow

See full
Operating cash flow-$39.2M-4.1%
CapEx$80.0K-9.1%
Free cash flow-$39.3M-4.1%

Valuation

See full
Market cap$3.31B+24.7%
Enterprise value$2.88B+38.1%
P/S464.5×+423×

Profitability

See full
Operating margin-3,432.2%-3,753pp
Net margin-3,644.2%-3,946pp
FCF margin-2,018.3%-2,259pp

Returns & leverage

See full
Return on equity-36.8%+15.4pp
Debt / equity0.0×
Current ratio-12.1×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333824
Line itemFor the three months ended June 30, 2026For the three months ended June 30, 2025For the six months ended June 30, 2026For the six months ended June 30, 2025
Foreign exchange gains/(losses)(526)8,626(2,139)12,919
Loss before tax(64,135)(17,364)(112,576)(56,891)
Income tax expense
Loss for the period(64,135)(17,364)(112,576)(56,891)
Other comprehensive income/(loss)
Unrealized gain/(loss) on available-for-sale securities, net of tax(360)(107)(932)(140)
Total comprehensive loss for the period, net of tax(64,495)(17,471)(113,508)(57,031)
Net loss per ordinary share

Item 1. Financial Statements.

FAQ

What is NewAmsterdam Pharma Company's net income?
NewAmsterdam Pharma Company (NAMS) reported net income of -$64.14M in Q2 2026.
How has NewAmsterdam Pharma Company's net income changed year-over-year?
NewAmsterdam Pharma Company's net income decreased by 269.4% year-over-year, from -$17.36M to -$64.14M.
What is the long-term trend for NewAmsterdam Pharma Company's net income?
Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's net income has grown at a 48.6% compound annual growth rate (CAGR), from -$41.79M to -$203.82M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about NewAmsterdam Pharma Company's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude